CST1与胰腺癌早期诊断：进展与展望

CST1 and Early Detection of Pancreatic Cancer: Progress and Prospects

摘要: 胰腺导管腺癌(Pancreatic Ductal Adenocarcinoma, PDAC)恶性度高、进展隐匿，临床确诊多已失去根治性切除时机，早期识别仍是改善预后的关键环节。围绕“可进入体液检测，并能补足CA19-9不足的候选分泌蛋白”这一需求，本文对PDAC早诊标志物与液体活检研究脉络进行归纳，并重点梳理Cystatin SN (CST1)的生物学特征、检测可行性及与肿瘤进展相关的证据。现有研究显示，ctDNA、CTCs、外泌体及非编码RNA等手段不断推进早诊探索，但受样本量、方法学差异与标准化不足等因素影响，临床可推广性仍有限。CST1属于II型cystatin家族，参与蛋白酶抑制网络失衡调控，在多种消化系统肿瘤中常见上调，并与增殖、迁移、上皮间质转化等过程相关；在PDAC领域，组织高表达与促肿瘤效应已有初步证据，但血清或外泌体层面的诊断效能、动态变化及外部验证仍明显不足。总体而言，CST1更可能作为联合面板的组成部分而非单一筛查指标，其真实增益有赖于前瞻性、多中心研究及统一检测与阈值体系的建立；未来应在高危人群随访与影像不确定人群中检验其临床价值。

Abstract: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid tumors, largely because early disease is clinically silent and current diagnostic pathways rarely identify patients at a stage amenable to curative resection. Although serum CA19-9 is widely used, its performance is constrained by limited sensitivity for early stage tumors, false positives in benign biliary and inflammatory conditions, and biological false negatives in Lewis antigen negative individuals, leaving a substantial gap between clinical need and available tools. With this gap in mind, the present review synthesizes the evolving landscape of PDAC early detection biomarkers and focuses on Cystatin SN (CST1) as a secreted, technically measurable protein candidate that could complement existing strategies. Evidence was appraised by integrating mechanistic findings with clinically oriented studies, with particular attention to specimen type, assay feasibility, study design, and the degree to which results are validated beyond single center case control settings. Across the field, liquid biopsy approaches such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles including exosomes, and circulating noncoding RNAs have expanded the spectrum of candidate signals. ctDNA enables detection of recurrent driver alterations and provides a direct molecular readout of tumor derived material, yet its sensitivity drops markedly in early stage PDAC where tumor shedding is low, and technical factors such as analytical limits of detection, platform variability, and interference from clonal hematopoiesis complicate interpretation. CTC based assays offer biologically rich information, but the rarity of CTCs in PDAC, phenotypic heterogeneity, and incomplete capture by single marker enrichment methods restrict robust application. Exosome associated cargos, including proteins and nucleic acids, are attractive because vesicular membranes protect contents from degradation and may better reflect tumor microenvironmental crosstalk; however, differences in isolation methods, yield and purity, and the absence of harmonized preanalytical workflows continue to drive between study variability. Circulating miRNA signatures and other noncoding RNAs have shown encouraging diagnostic accuracy in some cohorts, but signal specificity remains vulnerable to confounding by inflammation, pancreatitis, metabolic status, and sample handling. These collective experiences point to a recurring pattern: promising performance in selected cohorts often attenuates when moving toward heterogeneous real world populations, underscoring the importance of standardized assays, appropriate control groups, and external validation. Within this broader context, secreted proteins retain practical advantages because they are compatible with mature clinical laboratory platforms and may be integrated into existing workflows at lower marginal cost than sequencing based assays. CST1 is a member of the type II cystatin family and participates in the cathepsin cystatin protease inhibitor network, which has long been implicated in extracellular matrix remodeling, invasion, and metastatic dissemination. Unlike intracellular cystatins, type II cystatins are secreted into extracellular fluids, a feature that supports measurement in serum or plasma and increases translational plausibility for screening or surveillance applications. Across multiple gastrointestinal malignancies, CST1 is frequently reported to be upregulated and to correlate with aggressive phenotypes and poorer outcomes. Mechanistic studies indicate that CST1 may influence tumor progression by reshaping protease inhibitor balance and engaging oncogenic signaling programs, including pathways linked to proliferation, migration, epithelial mesenchymal transition, and stress adaptation. In PDAC specifically, currently available evidence supports elevated CST1 expression in tumor tissue and suggests pro tumor effects in experimental systems, which together provide biological rationale for further evaluation. At the same time, clinically decisive evidence remains incomplete. Data directly assessing serum or exosomal CST1 in well characterized PDAC cohorts are limited, and key questions remain open, including whether CST1 rises early enough to support detection of resectable tumors, how its levels behave longitudinally during treatment, and how strongly they are influenced by common clinical confounders such as cholestasis, systemic inflammation, renal function, or hemolysis. In addition, cut off selection, batch effects, and platform specific calibration can materially alter performance metrics, making cross study comparisons difficult without shared reference standards. Taken together, CST1 is best viewed at present as a candidate component of a multi marker panel rather than a stand alone screening test, with the most realistic use cases being high risk surveillance, triage of indeterminate imaging findings, or augmentation of CA19-9 based decision making. Future work should prioritize multicenter prospective validation enriched for early stage disease, rigorous control selection that includes benign biliary and inflammatory conditions, and harmonized preanalytical and analytical protocols so that the incremental value of CST1 can be quantified in clinically relevant pathways.